A significant ratio of late preterm infants receives surfactant therapy (ST) for respiratory
distress syndrome (RDS) and for other neonatal lung diseases characterized by surfactant …

Sir: Respiratory syncytial virus (RSV) is the most common cause of acute viral disease of the
lower respiratory tract in infants and children, and is the agent responsible for bronchiolitis …

Background Respiratory distress syndrome (RDS) is characterized by a lack of lung
surfactant; therefore, biochemical evidence of surfactant deficiency is needed to diagnose …

Surfactant replacement therapy has become an established treatment for neonatal
respiratory distress syndrome (RDS). This article reviews the current evidence for the …

Background: The cornerstone of the treatment of respiratory distress syndrome (RDS) is
respiratory support and surfactant replacement therapy. The administration of surfactant …

Surfactant treatment is standard of care for infants who have respiratory distress syndrome
(RDS). However, many practical questions remain about what RDS is, and who should be …

Objective: To determine if there is a relationship between acute improvement in pulmonary
gas exchange and surfactant use in near-term (35–39 weeks' gestation) infants with …

Douglas F. Willson, Patricia R. Chess, Zhengdong Wang, and Robert H. Notter dampened
by initial unsuccessful attempts by Robillard et al.[9] and Chu et al.[10, 11] in the 1960s to …

Objective Respiratory distress syndrome (RDS) is a major cause of morbidity and mortality in
preterm neonates. Pulmonary surfactant deficiency is the primary cause of RDS. The …

Surfactant deficiency in premature neonates is a major factor in the development of
respiratory distress syndrome (RDS), which is still a significant cause of mortality and …